<DOC>
	<DOCNO>NCT01462565</DOCNO>
	<brief_summary>The purpose multicentre , open label , single-arm study approximately 20 adult patient evaluate Impact lifestyle new thermo stable formulation epoprostenol sodium subject Pulmonary Arterial Hypertension ( PAH ) .</brief_summary>
	<brief_title>Study New Thermo Stable Formulation Epoprostenol Sodium Treat Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description>This multicentre , open label , single-arm study approximately 20 adult patient ( 18 - 75 year old ) design evaluate Impact lifestyle new thermo stable formulation epoprostenol sodium subject Pulmonary Arterial Hypertension ( PAH ) . The co-primary objective 1 ) describe effect new thermo stable formulation epoprostenol sodium quality life 2 ) determine dose titration requirement patient switch currently market FLOLAN ( epoprostenol sodium ) new thermo stable formulation . Secondary objective include assess safety , tolerability efficacy thermo stable formulation epoprostenol sodium exploratory objective evaluate effect new thermo stable formulation epoprostenol sodium haemodynamic parameter subset subject . Subjects already receive FLOLAN ( epoprostenol sodium ) treatment PAH stable dose least 3 month stable dos PAH treatment least 30 day prior screen enrol . After screen visit , eligible subject 4-week run-in period exist FLOLAN ( epoprostenol sodium ) treatment . At end 4-week period , admit clinic baseline assessment switch study medication ( new thermo stable formulation epoprostenol sodium ) . Subjects remain hospital minimum 6 hour ensure clinical hemodynamic stability prior discharge . Subjects may stay hospital 24-48 hour switch new thermo stable formulation epoprostenol sodium discretion investigator . Dose titration requirement assess time discharge . Haemodynamic parameter obtain subgroup subject enrol centre collection haemodynamic data consider part standard care . Subjects receive study medication continuous intravenous infusion 4-week treatment period . Those complete 4-week treatment period option enter extension phase study continue receive new formulation .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<criteria>Adult male female least 18 75 year time screen . Subjects must FLOLAN ( epoprostenol sodium ) therapy pulmonary arterial hypertension ( PAH ) approve product label . Subjects must stable dos exist FLOLAN ( epoprostenol sodium ) treatment minimum 3 month prior screen . Subjects must stable dos current PAH treatment FLOLAN ( epoprostenol sodium ) last 30 day . Subjects must walk distance least 150 meter sixminute walk distance test ( 6MWD ) . This test must complete Screening Visit . A female subject eligible participate nonchildbearing potential childbearing potential , negative pregnancy test screen , agree use one contraception method list protocol . Subjects must competent understand information give Institutional Review Board ( IRB ) Independent Ethics Committee ( IEC ) approve informed consent form must sign form prior initiation study procedure . Subjects give FLOLAN ( epoprostenol sodium ) condition manner outside approve indication . Subjects congestive heart failure arise severe leave ventricular dysfunction . Subjects , without supplemental oxygen , rest arterial oxygen saturation ( SaO2 ) &lt; 90 % measure pulse oximetry screen . Subjects hospitalize emergency visit emergency room condition related PAH treatment PAH last 3 month . The subject 's clinical condition expect remain clinically stable duration study . Female subject pregnant breastfeeding . Subjects demonstrate noncompliance previous medical regimen . Subjects history abuse alcohol illicit drug within 1 year . Subjects diagnosis active hepatitis ( hepatitis B surface antibody hepatitis C antibody ) . Subjects participate clinical study involve another investigational drug device within four week screen . Subjects history malignancy within past 5 year , exception basal cell carcinoma skin situ carcinoma cervix . Any concurrent condition would affect safety subject opinion investigator best interest patient participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>flolan</keyword>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>thermo stable formulation</keyword>
	<keyword>epoprostenol sodium</keyword>
	<keyword>modify sterile diluent</keyword>
</DOC>